OR WAIT null SECS
The cell banks were created using current good manufacturing practices and can be used each time CombiGene produces new plasmids for the production of its gene therapy, CG01.
Cobra Biologics, a contract development and manufacturing organization, and CombiGene, a gene therapy company located in Sweden, announced on August 18, 2020 that Cobra has produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy, CG01.
According to a Cobra press release, the cell banks were created using current good manufacturing practices and can be used each time CombiGene produces new plasmids for the production of CG01.
"The fact that we now have the three master cell banks in place means that all further production of plasmids, used in the manufacturing of CG01, for the final preclinical and clinical studies as well as future treatments, take place from a stable and safe basis," said Karin Agerman, chief research and development officer, CombiGene, in the press release.
"The generation of DNA cell banks is the vital first step in the product commercialization journey,” said Peter Coleman, CEO, Cobra Biologics, in the press release. “Cobra is excited to continue that journey with CombiGene and their CG01 epilepsy gene therapy drug candidate."